Pfizer (NYSE:PFE) chairman & CEO Albert Bourla penned an open letter today setting an expected timeline for the company’s COVID-19 vaccine candidate.
The vaccine candidate, being developed in collaboration with BioNTech (NSDQ:BNTX), is among the top COVID-19 vaccines currently undergoing Phase 3 clinical trials and nearing potential regulatory authorization, should they prove safe and effective. Once the company can do that, it intends to apply for FDA emergency use authorization (EUA).
Get the full story at our sister site, Drug Discovery & Development.